Alessa Therapeutics Inc.
Alessa Therapeutics is focused on developing effective, localized, and sustained drug delivery therapies for early interception and treatment of prostate cancer and other proliferative disorders. Founded in 2018 based on technology developed at UCSF, the company aims to create innovative treatments that minimize systemic side effects and improve patient quality of life. Their pipeline includes implantable systems and clinical trials targeting prostate cancer and benign prostate hyperplasia, with a mission to change the treatment paradigm for early-stage cancers.
Industries
Nr. of Employees
small (1-50)
Alessa Therapeutics Inc.
Patents
Products
Bicalutamide-eluting implant for localized prostate delivery
An implantable device formulation designed to release an anti-androgen small molecule (bicalutamide) locally in prostate tissue for sustained periods to achieve therapeutic tissue concentrations while limiting systemic exposure; evaluated in first-in-human feasibility and Phase I studies.
Enzalutamide-eluting implant for localized prostate delivery
An implantable device formulation designed to release an anti-androgen small molecule (enzalutamide analogue) locally in prostate tissue for sustained high local drug concentrations while minimizing systemic exposure; under evaluation in a Phase I clinical study.
Bicalutamide-eluting implant for localized prostate delivery
An implantable device formulation designed to release an anti-androgen small molecule (bicalutamide) locally in prostate tissue for sustained periods to achieve therapeutic tissue concentrations while limiting systemic exposure; evaluated in first-in-human feasibility and Phase I studies.
Enzalutamide-eluting implant for localized prostate delivery
An implantable device formulation designed to release an anti-androgen small molecule (enzalutamide analogue) locally in prostate tissue for sustained high local drug concentrations while minimizing systemic exposure; under evaluation in a Phase I clinical study.
Services
Sponsorship and execution of first-in-human and Phase I clinical studies evaluating safety, tolerability, PK and preliminary efficacy of implantable localized drug delivery systems.
Establishing and managing research collaborations with pharmaceutical affiliates and venture partners to support R&D and clinical programs.
Development and refinement of implant insertion workflows and procedural protocols, including imaging guidance and percutaneous techniques, based on initial human feasibility cases.
Sponsorship and execution of first-in-human and Phase I clinical studies evaluating safety, tolerability, PK and preliminary efficacy of implantable localized drug delivery systems.
Establishing and managing research collaborations with pharmaceutical affiliates and venture partners to support R&D and clinical programs.
Development and refinement of implant insertion workflows and procedural protocols, including imaging guidance and percutaneous techniques, based on initial human feasibility cases.
Expertise Areas
- Localized implantable drug delivery
- Early-phase oncology clinical trials
- Drug–device combination product development
- Minimally-invasive image-guided implantation procedures
Key Technologies
- Drug-eluting implantable devices
- Sustained local drug release formulations
- Implantable drug–device combinations
- MRI fusion-guided implantation
News & Updates
Alessa Therapeutics announced the enrollment of the first patient in the Enolen clinical study at the NCI, evaluating localized delivery of enzalutamide for prostate cancer.
First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer
Alessa Therapeutics announced the enrollment of the first patient in Australia for the Biolen-PC study, evaluating localized delivery of bicalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first two men in the Biolen+RT clinical study in collaboration with the NCI, evaluating targeted local delivery of an anti-androgen agent.
Alessa Therapeutics announced the enrollment of the first patient in the Enolen clinical study at the NCI, evaluating localized delivery of enzalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first patient in Australia for the Biolen-PC study, evaluating localized delivery of bicalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first two men in the Biolen+RT clinical study in collaboration with the NCI, evaluating targeted local delivery of an anti-androgen agent.
Alessa Therapeutics announced the enrollment of the first patient in the Enolen clinical study at the NCI, evaluating localized delivery of enzalutamide for prostate cancer.
First Australian Patient Enrolled in Biolen-PC Study for Localized Drug Delivery for Prostate Cancer
Alessa Therapeutics announced the enrollment of the first patient in Australia for the Biolen-PC study, evaluating localized delivery of bicalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first two men in the Biolen+RT clinical study in collaboration with the NCI, evaluating targeted local delivery of an anti-androgen agent.
Alessa Therapeutics announced the enrollment of the first patient in the Enolen clinical study at the NCI, evaluating localized delivery of enzalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first patient in Australia for the Biolen-PC study, evaluating localized delivery of bicalutamide for prostate cancer.
Alessa Therapeutics announced the enrollment of the first two men in the Biolen+RT clinical study in collaboration with the NCI, evaluating targeted local delivery of an anti-androgen agent.